Caribou Biosciences (NASDAQ: CRBU) net income
Caribou Biosciences reported a net loss of $148.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $149.1m. Earnings per share were −$1.59.
Caribou Biosciences's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$148.1m | — | −1,327.4% | −$1.59 |
| 2024 | −$149.1m | — | −1,491.9% | −$1.65 |
| 2023 | −$102.1m | — | −296.1% | −$1.38 |
| 2022 | −$99.4m | — | −717.8% | −$1.64 |
| 2021 | −$66.9m | — | −697.3% | −$2.11 |
| 2020 | −$34.3m | — | −277.6% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Caribou Biosciences net income compared with its sector
By net income for its latest fiscal year, Caribou Biosciences ranks 381st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Caribou Biosciences, −1,327.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 379th | Amylyx Pharmaceuticals | −$144.7m | — |
| 380th | AbCellera Biologics | −$146.4m | −194.9% |
| 381st | Caribou Biosciences | −$148.1m | −1,327.4% |
| 382nd | UroGen Pharma | −$153.5m | −139.8% |
| 383rd | Crescent Biopharma | −$153.9m | −1,419.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Caribou Biosciences
- How much did Caribou Biosciences earn in fiscal 2025?
- Caribou Biosciences reported a net loss of $148.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $149.1m.
- What are the earnings per share of Caribou Biosciences?
- They were −$1.59 in fiscal 2025, compared with −$1.65 in fiscal 2024.
- Where does Caribou Biosciences rank in its sector by net income?
- It ranks 381st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Caribou Biosciences come from?
- From the annual report (Form 10-K) that Caribou Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Caribou Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Caribou Biosciences: the Caribou Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.